First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.

Glioblastoma multiforme (GBM) patients have a poor prognosis. After tumor recurrence statistics suggest an imminent death within 1-4.5 months. Supportive preclinical data, from a rat model, provided the rational for a prototype clinical vaccine preparation, named Gliovac (or ERC 1671) composed of autologous antigens, derived from the patient's surgically removed tumor tissue, which is administered together with allogeneic antigens from glioma tissue resected from other GBM patients. We now report the first results of the Gliovac treatment for treatment-resistant GBM patients. Nine (9) recurrent GBM patients, after standard of care treatment, including surgery radio- and chemotherapy temozolomide, and for US patients, also bevacizumab (Avastin™), were treated under a compassionate use/hospital exemption protocol. Gliovac was given intradermally, together with human GM-CSF (Leukine(®)), and preceded by a regimen of regulatory T cell-depleting, low-dose cyclophosphamide. Gliovac administration in patients that have failed standard of care therapies showed minimal toxicity and enhanced overall survival (OS). Six-month (26 weeks) survival for the nine Gliovac patients was 100% versus 33% in control group. At week 40, the published overall survival was 10% if recurrent, reoperated patients were not treated. In the Gliovac treated group, the survival at 40 weeks was 77%. Our data suggest that Gliovac has low toxicity and a promising efficacy. A phase II trial has recently been initiated in recurrent, bevacizumab naïve GBM patients (NCT01903330).

[1]  D. Morton,et al.  Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. , 2003, Seminars in cancer biology.

[2]  M. Weller,et al.  MIP-1α Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model , 2004, Journal of Neuro-Oncology.

[3]  M. Mansour,et al.  Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines , 2011, Cancers.

[4]  L. Deangelis,et al.  Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Armitage.  The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation. , 1992, Seminars in hematology (Print).

[6]  V. Sondak,et al.  Melacine®: an allogeneic melanoma tumor cell lysate vaccine , 2003, Expert review of vaccines.

[7]  R. Kerbel,et al.  Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models , 2009, Molecular Cancer Therapeutics.

[8]  E. Perkins,et al.  Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. , 1999, Neurosurgery.

[9]  M. Perales,et al.  Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines , 2004, Hematology.

[10]  G. Kaplan,et al.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing , 1992, The Journal of experimental medicine.

[11]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. , 1996, Blood.

[12]  P. Black,et al.  Scale to predict survival after surgery for recurrent glioblastoma multiforme. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Chamberlain,et al.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma , 2009, Journal of Neuro-Oncology.

[14]  V. Schijns,et al.  Trends in vaccine adjuvants , 2011, Expert review of vaccines.

[15]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[16]  O. Scharovsky,et al.  The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. , 2009, Oncology research.

[17]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[18]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Dranoff.  GM‐CSF‐based cancer vaccines , 2002, Immunological reviews.

[20]  Franco Patrone,et al.  The use of dendritic cells in cancer immunotherapy. , 2008, Critical reviews in oncology/hematology.

[21]  E. Rothstein,et al.  A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. , 2008, Vaccine.

[22]  P. Lowenstein,et al.  Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression , 2009, Clinical Cancer Research.

[23]  H. Maguire,et al.  Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Apuzzo,et al.  Cytokines and immunoregulatory molecules in malignant glial neoplasms. , 1992, Journal of neurosurgery.

[25]  M. Herrero,et al.  Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. , 2009, The American journal of pathology.

[26]  Thomas C Chen,et al.  Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. , 2015, The Permanente journal.

[27]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[28]  M. Prados,et al.  Survival and functional status after resection of recurrent glioblastoma multiforme. , 1998, Neurosurgery.

[29]  M. Chamberlain,et al.  Salvage therapy with single agent bendamustine for recurrent glioblastoma , 2011, Journal of Neuro-Oncology.

[30]  M. Chamberlain.  Bevacizumab for the Treatment of Recurrent Glioblastoma , 2011, Clinical Medicine Insights. Oncology.

[31]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Ruedl,et al.  Cutting Edge: Granulocyte-Macrophage Colony-Stimulating Factor Is the Major CD8+ T Cell-Derived Licensing Factor for Dendritic Cell Activation , 2010, The Journal of Immunology.

[33]  I. Yang,et al.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival , 2010, Journal of Clinical Neuroscience.

[34]  J. Gui,et al.  Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. , 2011, Neuro-oncology.